Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRd in Newly Diagnosed Transplant Eligible Myeloma
NCT03376672Phase 2Active, not recruiting
- Start
- May 2018
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of ixazomib in multiple myeloma (MM). Started May 2018; status: active, not recruiting.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03376672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03376672.